Earlier studies conducted by our laboratory have shown that suppression of transforming growth factor-b (TGFb)mediated upregulation of connective tissue growth factor (CTGF) by iloprost resulted in a greatly diminished oval cell response to 2-acetylaminofluorene/partial hepatectomy (2AAF/PH) in rats. We hypothesized that this effect is due to decreased activation of hepatic stellate cells. To test this hypothesis, we maintained rats on a diet supplemented with 2% L-cysteine as a means of inhibiting stellate cell activation during the oval cell response to 2AAF/PH. In vitro experiments show that L-cysteine did, indeed, prevent the activation of stellate cells while exerting no direct effect on oval cells. Desmin immunostaining of liver sections from 2AAF/PH animals indicated that maintenance on the L-cysteine diet resulted in an 11.1-fold decrease in the number of activated stellate cells within the periportal zones. The total number of cells proliferating in the periportal zones of livers from animals treated with L-cysteine was drastically reduced. Further analyses showed a greater than fourfold decrease in the magnitude of the oval cell response in animals maintained on the L-cysteine diet as determined by immunostaining for both OV6 and a-fetoprotein (AFP). Global liver expression of AFP as measured by real-time PCR was shown to be decreased 4.7-fold in the L-cysteine-treated animals. These data indicate that the activation of hepatic stellate cells is required for an appropriate oval cell response to 2AAF/PH.
Progenitor cell therapies for liver pathologies that result in massive loss of hepatic parenchyma are one alternative to liver transplantation. The 'oval cell' is the facultative hepatic progenitor cell, which aids in liver regeneration when the proliferation capacity of mature hepatocytes is compromised. These cells are bipotential (ie, capable of differentiation down both the hepatocyte and biliary lineages) and are thought to reside within the portal zones of the liver at the canals of Hering. 1 A number of human conditions are associated with oval cell proliferation; among these are infections by hepatotropic viruses and terminal stages of liver cirrhosis. 2 Earlier data from our laboratory suggest a coordinated interaction among the various hepatic cell types during the regeneration process, particularly between hepatic stellate cells and oval cells. 3 Their co-activation has been shown in the 2-acetylaminofluorene/partial hepatectomy (2AAF/PH) model as well as several other liver remodeling processes, including hepatic fibrosis 4 and liver regeneration after PH or D-galactosamine exposure. 5 Under physiological conditions, stellate cells are quiescent, exhibiting vitamin A droplets and a star-like morphology. Their activation is followed by proliferation and differentiation into contractile myofibroblast-like cells. Known for their contribution to extracellular matrix (ECM) synthesis and remodeling, and as an important source of cytokines and growth factors, activated stellate cells are also responsible for the excessive fibrosis observed in liver cirrhosis. 6 Disruption of the transforming growth factor-b (TGFb)-CTGF signaling axis by the prostacyclin analogue iloprost resulted in a significant reduction of oval cell proliferation. 3 As TGFb has such a complex range of actions on various cell types, we further explored whether these effects are the result of stellate cell inhibition, or are attributable to other interactions within the regenerating liver. L-cysteine is a non-essential amino acid, widely used as a nutritional supplement, antioxidant and mucolytic agent. Recent data suggest that it might also be a potent inhibitor of liver fibrosis, acting to prevent stellate cell activation. 7 Its complex effects on the liver are attributed to various mechanisms, including: synthesis of glutathione 8, 9 ; reactive oxygen species-mediated degradation of cyclin D1 with subsequent activation of manganese superoxide dismutase 10 ; downregulation of platelet-derived growth factor receptor-b (PDGFRb) and inhibition of platelet-derived growth factor (PDGF) signaling. 11, 12 Despite the various putative mechanisms of action, it is widely accepted as a potent, harmless inhibitor of hepatic stellate cells and was proposed as an adjuvant therapy for human cirrhosis. To test our hypothesis that the stellate cells have a necessary function in facilitating oval cell proliferation, a diet supplemented with L-cysteine was combined with the well-characterized 2AAF/PH protocol 13, 14 for oval cell activation in rats. This study clearly shows that hepatic stellate cell activation is required for a robust oval cell response to 2AAF/PH.
MATERIALS AND METHODS Animal Treatments
The animal procedures involved in this study were conducted with the approval of the University of Florida IACUC. Sixweek-old Fisher 344 male rats (Charles River Laboratories, Wilmington, MA, USA) were maintained on standard laboratory chow supplemented with 2% L-cysteine (Dyets, Betlehem, PA, USA) for the duration of the experiment, according to a protocol established by Horie et al. 7 One month after the initiation of the diet, 70 mg 2AAF pellets (Innovative Research of America, Sarasota, FL, USA) were implanted intraperitoneally and, 1 week later, a 70% PH was performed as described by Higgins and Anderson. 15 The animals were sacrificed at defined time points as indicated in Figure 1 . Tissue samples were collected and preserved by formaldehyde fixation or frozen in OCT compound (Sakura Finetek USA, Torrance, CA, USA).
Cell Culture and Bromodeoxyuridine Labeling WB-F344 oval cells (kindly provided by Dr William Coleman) were cultured at 371C, 5% CO 2 in RPMI-1640 medium (Mediatech, Herndon, VA, USA) supplemented with 10% FBS (Sigma Aldrich, St Louis, MO, USA) and 1% penicillin-streptomycin (Mediatech). Primary isolated portal fibroblasts and HSC-T6 hepatic stellate cells (kind gifts from Drs Rebecca Wells and Scott Friedman, respectively) were cultured under the same conditions in DMEM (Hyclone Lab, Logan, UT, USA) with 10% FBS and 1% penicillinstreptomycin. When 30% confluence was achieved, they were synchronized for 24 h with 0.4 mg/ml Demecolcine (Sigma Aldrich) and treated with 100 mM L-cysteine (MP Biomedicals LLC, Cleveland, OH, USA), thus inhibiting the hepatic stellate cell activation. After a 3-day exposure to L-cysteine, the chamberslides were treated with 10 mM bromodeoxyuridine (BrdU) (Sigma Aldrich) and fixed in 4% paraformaldehyde.
Histology and Immunohistochemistry
Paraffin embedded or frozen liver sections cut to 5 mm thickness were stained with hematoxylin and eosin or immunostained using anti-OV6 (courtesy of Dr Stewart Sell), anti-Ki67 (BD Biosciences Pharmingen, Franklin Lakes, NJ, USA) or anti-a-fetoprotein (Dako Cytochromatin, Carpinteria, CA, USA) antibodies. Anti-desmin antibody (Dako Cytochromatin) was also used for stellate cell immunostaining. Paraformaldehyde-fixed chamberslides were immunostained using anti-BrdU antibody (Dako Cytochromatin). Computer image analyses of immunostained sections were performed using Aperio ScanScope Image Analysis Platform (Aperio, Vista, CA, USA) and MetaMorph software (MDS Technologies, Concord ON, Canada) for histological evaluation and quantitation.
Real-Time Quantitative PCR
The mRNA levels were assessed by two-step quantitative real-time PCR reaction, using a DNA Engine Opticon 2 Continuously Fluorescence Detector (MJ Research, Waltham, MA, USA). Total RNA was extracted using the RNA Bee isolation kit (Tell-Test, Friendswood, TX, USA), treated with DNase I (Ambion, Austin, TX, USA) and reverse transcribed with the Superscript III First Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA). Amplification was performed on a customized RT2Profiler PCR Array plate for the genes of interest (SA Biosciences, Frederick, MD, USA) using iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA). The primer pair used was: forward CAGGAGGAAGAAAGGACAAAAAA and reverse ATTCCTA AGGCATAGAAATCCCA. The amplification conditions were 10 min at 951C, followed by 40 cycles of 15 s at 951C, 30 s at 551C, 30 s at 721C. The comparative Ct threshold cycle method was used to assess the expression level, normalized to b-actin mRNA expression.
Statistical Analysis
Values were expressed as mean ± s.d. Statistical significance was determined by analysis of variance, and Student t-test performed in Microsoft Excel. P-values o0.05 were considered to be statistically significant. 
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RESULTS L-Cysteine Appears to be a Selective In Vitro Inhibitor of Hepatic Mesenchymal Populations
We first examined the in vitro effects of L-cysteine on several hepatic cell populations in culture. S-phase cells were identified by BrdU incorporation into newly synthesized DNA. To exclude the possibility that L-cysteine acts directly on oval cells, the hepatic progenitor cell line, WB-F344 was cultured both with and without (Figures 2a and d , respectively) 100 mM L-cysteine. As expected, treatment with L-cysteine had no effect on the proliferation rate of these cells ( Figure 3 ). We next examined primary portal fibroblast cultures (Figures 2b and e ), as well as the hepatic stellate cell line HSC-T6 (Figures 2c and f) . In contrast to the progenitor cell line, both of the mesenchymal cell cultures showed a significant reduction in proliferation rates when culture media was supplemented with 100 mM L-cysteine. A 3.56-fold decrease in BrdU incorporation for HSC-T6 and a 5.6-fold reduction for portal fibroblasts were observed (Figures 2e and f). Taken together, quantitative image analysis data indicate that L-cysteine acts selectively on the mesenchymal cell populations examined ( Figure 3 ).
Histological Changes in Oval Cell Activation Under L-Cysteine Diet
Histological characterization of liver regeneration in the 2AAF/PH model for oval cell activation in rats showed the expected robust proliferation of small cells emanating from the periportal zone (Figures 4b and e ). These small oval-shaped cells were not present in untreated rat liver (Figures 4a and e ). In animals that were maintained on the 2% L-cysteine diet, the small cell response in the portal zone remained quite modest (Figures 4c and f) . The disparity between the amplitude of the small cell response in the two groups was most evident on day 9 post-PH. This time point is known to coincide with the peak of oval cell proliferation after 2AAF/PH activation protocol in rats. Aside from the reduced small cell presence in L-cysteine-treated animals, there is also a notable difference in cell morphology. In the L-cysteine-treated group, some cells tended to be larger (over 10 mm diameter), with a slightly reduced nucleus to cytoplasm ratio, more rounded nuclei and basophilic vacuolar cytoplasm, bearing a resemblance to a small hepatocyte-like cell.
Hepatic Stellate Cell Activation is Inhibited by L-Cysteine Diet in the 2AAF/PH Model Definitive identification of activated hepatic stellate cells in microscopic liver sections was accomplished by immunostaining for desmin, a cytoskeleton intermediary filament which, in rat liver, is expressed only by activated stellate cells. 16 Hepatic stellate cells are present in very low numbers in normal liver tissue (Figures 5a and d ). However, they proliferate and migrate in close proximity to the regenerating oval cells in the 2AAF/PH model (Figures 5b and e ). In animals treated with L-cysteine, considerably fewer desminpositive cells are apparent after 2AAF/PH (Figures 5c and f). 
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Quantitative computer image analysis showed a 411-fold decrease in the number of desmin-positive cells in 2AAF/PH rats maintained on the L-cysteine diet as compared with 2AAF/PH animals that received the standard diet (Figure 5g ). These results suggest that the inhibitory effects of L-cysteine on hepatic stellate cell activation work as expected in our 2AAF/PH model of oval cell induction.
L-Cysteine Exposure is Associated with Reduced Cell Proliferation in Periportal Areas
We next sought to determine the proliferation status of the cells within the periportal zones of livers from 2AAF/PHtreated animals both with, and without the L-cysteine diet. Proliferation was determined by immunostaining for Ki67 nuclear antigen on day 9 after PH. Ki67 identifies all cells that are not in G 0 . In the normal liver, very few hepatocytes proliferate in the absence of an injury (Figure 6a) . A large number of proliferating cells were present in the portal zones of the livers of rats subjected to the 2AAF/PH protocol (Figure 6b ). A greater than threefold reduction in the number of proliferating cells was measured in the portal zones of the livers from rats maintained on the L-cysteine diet (Figures 6c  and d ). Figures 7a and d) . The numerous proliferating cells in the periportal areas of 2AAF/PH exposed animals were surrounded by desmin-positive cytoplasmic projections (Figures 7b and e ). Sections collected from animals kept on L-cysteine diet exhibited a reduced presence of proliferating 
Reduced Cell Proliferation in Periportal Areas
Regenerating Cells in the Periportal Areas are AFP and OV6 Positive
To identify the oval cell population within the portal zone on day 9 after 2AAF/PH, paraffin sections were stained for a-fetoprotein (AFP). On the normal liver sections, no AFPpositive cells were apparent (Figures 8a and d) . As expected, the portal zones of livers from 2AAF/PH-treated animals contained a large population of AFP-positive cells (Figures 8b  and e ). Animals exposed to L-cysteine showed a greater than fourfold decrease in AFP-positive cells (Figures 8c, f and g) .
It is worth noting that a greater percentage of the cells within the portal zones of livers from animals maintained on the L-cysteine diet appeared to be transitional hepatocytes (ie, larger, hepatocyte-like cells with weak expression of AFP). Global AFP expression in the livers of animals subjected to 2AAF/PH was determined by quantitative real-time PCR (Figure 9a ). AFP message was measured relative to the normal liver and normalized to b-actin. Animals that were exposed to L-cysteine showed a 4.7-fold decrease in total liver expression of AFP as compared with animals that were fed the normal diet. These results suggest a significant reduction of oval cell contribution to hepatic mass recovery. 
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An alternative oval cell marker was used to confirm the findings of the AFP immunostaining. OV6 is a wellcharacterized marker for oval cells and bile duct cells. In normal liver, only the bile ducts within the portal triad were positive for OV6 (Figures 10a and d) . Liver samples from animals subjected to 2AAF/PH contained a large population of OV6-positive cells within the periportal zone that radiated out toward the central vein (Figures 10b and e ). This is consistent with a normal oval cell response at day 9 after PH in the 2AAF/PH model. In contrast to this, the liver sections from animals maintained on the L-cysteine diet displayed a very modest oval cell response at day 9 after PH (Figures 10c  and f) . Computer image analysis of scanned slides confirmed the 3.5-fold disparity in the magnitude of oval cell response in animals that were fed the normal rat food, as compared with animals that were administered L-cysteine (Figure 10g ).
DISCUSSION
Progenitor cell-mediated liver regeneration is an alternative compensatory hyperplasia, able to restore hepatic mass when hepatocyte proliferation is severely impaired by massive liver necrosis or chronic cirrhogenic conditions. 17 Oval cells and stellate cells are among the first cells to enter the cell cycle after 2AAF/PH progenitor activation protocol. 18 Less is known regarding the exact temporal relationship between oval and stellate cell activation in the regenerating liver. It is for this reason that we chose to begin the L-cysteine diet well before the initiation of the 2AAF/PH protocol (Figure 1) . The daily food intake and the body weight of all animals were monitored for the duration of the study to identify any potential effects attributable to the diet, and no significant differences were seen between animals fed the experimental and control diets. Our in vitro studies also show that (Figure 2 ). Taken together, these facts indicate that the effects of L-cysteine in our model result from the specific inhibition of hepatic stellate cells. The hepatocyte proliferation inhibitor 2AAF is activated and detoxified by the liver through rounds of hydroxylation and conjugation, 19 which lead to renal excretion of watersoluble derivatives. 20, 21 Being a precursor for glutathione synthesis, it is reasonable to consider the possibility that L-cysteine could increase the rate of 2AAF detoxification. This would potentially lead to incomplete suppression of hepatocyte proliferation in the 2AAF/PH model. However, examination of Ki67-stained liver sections from the L-cysteine-treated group showed no signs of mature hepatocyte proliferation, the only Ki67-positive cells being oval cells and small hepatocyte-like phenotype (Figure 6 ). This would seem to exclude differential 2AAF metabolism as a complicating factor in these studies. The reduced Ki67 presence in the animals maintained on L-cysteine was associated with a diminished presence of desmin in the periportal spaces, indicating a reduced activation of hepatic stellate cells. Under these circumstances, the number of proliferating cells in the periportal areas was also reduced, suggesting an association between a reduced contribution of stellate cells and diminished hepatic regeneration (Figures 7c and f as opposed to Figures 7b and e ).
Progenitor cell-mediated liver regeneration is a complex process, involving sequential waves of cytokine secretion and remodeling of the ECM. These two processes are intimately coupled, as the matrix can liberate chemical signals when degraded, and concentrate chemical signals 22 that bind to the matrix within specific regions. 23, 24 Thus, ECM functions as a primary reservoir of biologically active molecules in the liver. 18 During hepatic regeneration, the presence of increased numbers of hepatic stellate cells was noted in close proximity to the oval cells. 25 Activated hepatic stellate cells are the main source of MMPs and TIMPS that participate in matrix remodeling and release of bound cytokines. 18, 26 Matrix remodeling results in the establishment of a unique microenvironment, conducive for the proliferation and migration of cells within the regenerating zone. This renders the activation of hepatic stellate cells a critical component of progenitor cell-mediated liver regeneration process. Earlier research conducted by our group shows that during progenitor cell-mediated liver regeneration, a fibronectin-rich provisional matrix is synthesized in the portal zone. 23 We feel that it is likely that this provisional matrix contributes to the oval cell response, acting as a required substrate on which oval cells may proliferate and providing binding sites for signaling molecules that regulate oval cell phenotype. One such example is CTGF, which binds to the fibronectin-rich provisional matrix of the periportal zone, where it is concentrated and made available to the oval cells, which are known to express CTGF receptors. 23 Several recently published studies clearly show that stellate cells within the liver may, through a process of mesenchymal to epithelial transition, give rise to hepatocytes. 27 It is possible that this phenomenon involves an intermediate cell type with oval cell properties. It is impossible to determine whether decreased mesenchymal to epithelial transition contributes to the reduction in oval cell proliferation seen in our model. However, this possibility deserves mention.
Another interesting feature of the L-cysteine-treated livers is the apparent accumulation of transitional or intermediate hepatocytes (Figure 4) , displaying a phenotype characteristic for the regeneration process, without any alterations induced by the diet. These cells are morphologically similar to hepatocytes, but are much smaller and weakly express AFP. In our model, we speculate that these cells are oval cells that have failed to complete the differentiation program, but at this stage, the absence of reliable markers has made their precise identification impossible. This would suggest that inhibition of stellate cell activation after 2AAF/PH not only affects oval cell proliferation, but also oval cell differentiation. Once again, this would most likely result from the lack of an appropriate microenvironment within the regenerating zone and advocates the 'nurturing role' of stellate cells during the regeneration process. Although the cellular proliferation appears to be attenuated quantitatively in response to stellate cell inhibition, we have not noticed any phenotype alterations of the oval cells during the regeneration process. Overall, the blunted oval cell response in animals fed the L-cysteine diet is likely due to a combination of the loss of a major cytokine Interactions between stellate and oval cells DG Pintilie et al source (ie, activated stellate cells), coupled with the loss of an appropriate microenvironment for the expansion of the oval cell population (ie, the fibronectin-rich provisional matrix). The end result of L-cysteine treatment is a rough doubling of the time required for the regeneration of the liver after 2AAF/ PH (data not shown). As the injury does eventually resolve in the L-cysteine-treated group, redundant pathways for the regulation of oval cell phenotype likely exist. However, the significant reduction in the oval cells seen at what would normally be considered the time of maximal oval cell proliferation proves, for the first time, the critical role of stellate cells in oval cell-mediated liver regeneration. Interactions between stellate and oval cells DG Pintilie et al
